Top 50 Cell Line Development in Latin America

CellRep develops cell reprogramming strategies to enhance T cell functionality, increasing their therapeutic potential for cancer and chronic conditions. The company provides an end-to-end pipeline from target discovery to preclinical validation, enabling more effective cell therapies for patients.

EdgeQ develops a Base Station-on-a-Chip that integrates 4G and 5G technologies for small and macro cell deployments, enabling customizable and field-deployable solutions compliant with 3GPP standards. This technology addresses the need for efficient, low-power wireless infrastructure to enhance network coverage and support mission-critical applications in various environments.

This startup provides cell-based bioingredients through advanced cell culture techniques, enabling the production of plant-based meat without harming animals. Their approach offers consumers healthier ingredients while addressing the demand for sustainable food alternatives.

The company develops immune cell-based therapies utilizing gamma delta T-cells for the off-the-shelf treatment of breast, ovarian, and prostate cancers. This approach addresses the limitations of existing cancer immunotherapies by providing a more accessible and effective treatment option for patients.

Exomas is developing a regenerative therapeutic platform using neural stem cell-derived exosomes to treat neurodegenerative diseases. Their CBSD-EXO technology stimulates endogenous neural stem cell proliferation and promotes neurogenesis to restore neuronal function and mitigate cognitive and motor impairments.

Develops senoblockers, a novel class of therapeutics that target epigenetic regulators to reverse cellular senescence and restore stem cell activity. This approach addresses the decline in regenerative capacity and the accumulation of senescent cells, which are key contributors to age-related diseases.

Swift Solar develops lightweight and flexible photovoltaic cells using engineered perovskite tandem technology, which efficiently absorbs the solar spectrum to maximize power output. By manufacturing these cells domestically, the company reduces carbon emissions and mitigates supply chain risks, enabling scalable production to meet global energy demands.

Elegen utilizes proprietary cell-free DNA synthesis technology to produce long, complex, linear DNA up to 7 kb with 99.999% accuracy, eliminating the need for cloning. This rapid synthesis, delivered in 6 to 8 business days, addresses the critical bottleneck in DNA supply for synthetic biology applications, significantly reducing project timelines and costs.

This startup produces frozen meals using artificial intelligence and cellular agriculture to create environmentally friendly food options. Their ready-to-eat products, such as breaded chicken and veggie cutlets, provide customers with convenient, responsibly sourced meals that are easy to store.

Guska develops synthetic RNA oncolytic virus therapies that precisely target and eliminate cancer cells while stimulating the immune system. This approach offers a more effective and less harmful alternative to traditional cancer treatments by enhancing the body's ability to fight tumors.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Longevity Medical Institute offers advanced regenerative therapies and integrated diagnostics to improve healthspan and vitality. They provide personalized treatment protocols using stem cell and exosome therapies, alongside AI-enhanced imaging and comprehensive laboratory analysis for age-related and chronic conditions.

Botanical Solution Inc. utilizes proprietary plant tissue culture technology to produce advanced botanical materials from the Quillaja saponaria tree, ensuring a sustainable and scalable supply of key ingredients for the agricultural and pharmaceutical industries. This approach addresses the supply and quality issues associated with traditional botanical raw materials, enabling the development of effective products like the biofungicide Quillibrium® and the vaccine adjuvant QS-21.

This biotech startup produces highly pure enzymes using recombinant DNA repair technology derived from Antarctic extremophiles, enabling large-scale replication of active ingredients. Their offerings provide clinicians with effective alternatives for skin health and rejuvenation in the cosmetic and pharmaceutical industries.

The startup has developed a proprietary platform for engineering proteins that enables the self-assembly of viral proteins and the creation of nanobiodevices and nanobiomaterials. This technology facilitates advancements in immunotherapy, vaccine development, and personalized medicine, providing clients with effective solutions for diagnostics and therapeutics.

Trebe Biotech utilizes insect larvae as biofactories to produce high-quality recombinant proteins and vaccines, offering a sustainable and cost-effective alternative to traditional bioreactor methods. This approach addresses the need for rapid production of bioproducts, particularly in response to emerging health challenges in both human and veterinary medicine.

Rosebud Biosciences develops targeted therapies for rare genetic diseases in children by utilizing organoids that replicate specific genetic mutations, allowing for precise drug screening. This approach addresses the critical lack of approved treatments for 95% of rare diseases, significantly improving the potential for effective cures.

Aperture Therapeutics develops a drug discovery engine that utilizes extensive cell libraries representing genetic diversity to identify gene variants that confer protection against neurodegenerative diseases. By targeting specific RNA transcripts, the company aims to create therapies that can delay brain aging and improve outcomes for affected populations.

Terraflos utilizes synthetic biology and cellular agriculture to produce high-value bioactive compounds from plant genetic information and stem cells, minimizing environmental impact. The startup addresses the growing demand for sustainable health and wellness solutions by providing optimized active ingredients for the cosmetic, food, nutraceutical, and pharmaceutical industries.

Neocrop Technologies accelerates crop improvement using its Neotrait Engine®, which combines CRISPR gene editing, speed-breeding, and proprietary software to rapidly develop new seed varieties. The platform delivers traits like drought tolerance and enhanced nutrition, significantly shortening the breeding cycle for commercial partners.

The startup utilizes a bio-based technological platform that employs genetic engineering tools and microalgae to produce valuable proteins and compounds, such as hirudin, which is traditionally sourced from sponges. This approach provides a sustainable and cost-effective solution for companies seeking hard-to-find biochemical compounds.

CytoEM Innovations decodes the electromagnetic identity of various cell types to precisely control their growth and behavior through interferometry. This technology addresses the challenges of low cell yield and high production costs in bioprocesses, enhancing efficiency in pharmaceutical and agricultural applications.

Base Cientifica offers comprehensive molecular and cellular research services to accelerate preclinical development and personalized medicine. They specialize in biological assay validation, biobanking, and molecular diagnostic assay development using PCR and NGS. Their services also include preclinical efficacy and safety studies, 3D organoid cultivation, and AI-driven R&D optimization.

This startup provides biotechnology services focused on developing industrial yeast strains and optimizing fermentation processes through advanced yeast metabolism and genetics research. Their solutions enable the yeast and fermentation industries to produce environmentally friendly products using renewable resources, addressing the need for sustainable manufacturing practices.

Luyef utilizes cellular agriculture techniques to produce animal-free meat alternatives that replicate the taste, texture, and structure of conventional meat. This approach significantly reduces land use by over 95% and greenhouse gas emissions by up to 92%, addressing the ethical and environmental issues associated with traditional livestock farming.

The startup develops gene therapies utilizing a biocompatible delivery system to facilitate targeted treatment of genetic diseases. This approach enhances the efficacy of therapeutic interventions, addressing the limitations of traditional treatment methods in the biotechnological market.

Celentis develops novel therapeutic solutions by leveraging advanced biotechnology research. The company focuses on creating innovative treatments for unmet medical needs, aiming to improve patient outcomes.

The startup utilizes a proprietary Generative Biology Platform and a Discovery Platform that integrate machine learning and multi-modal single-cell analysis to identify gene regulatory networks and develop targeted cell therapies for cancer. By precisely modulating gene expression in specific cell types, the company aims to enhance the efficacy of cell-based treatments, addressing the limitations of traditional cancer therapies.

This startup has developed a biotech platform that enhances the drug discovery process through predictive toxicology and drug quality assurance, specifically tailored for the Latin American market. By optimizing research and development workflows, the platform reduces time and costs while minimizing the reliance on animal testing.

Mercury Bio has developed a proprietary chimeric extracellular vesicle (yEV™) platform that delivers ribonucleic acid and small-molecule drugs to specific cells, enhancing drug potency while minimizing side effects. This technology addresses the challenge of effective therapeutic delivery by enabling targeted treatment of viral diseases, cancer, and inflammatory conditions without triggering an immune response.

Inkus provides genetic and genomic solutions to enhance the productivity and resilience of aquaculture species through precision breeding techniques. The startup addresses the challenges of low yield and vulnerability to disease in the aquaculture industry, enabling sustainable growth and improved stock performance.

WaveComm Tech provides custom Software Defined Radio (SDR) waveform development and system integration for defense and public safety sectors. They deliver tailored wireless communication solutions with expertise in electronic warfare, signals intelligence, and cybersecurity.

Asclepii develops Artemis™, a scalable tissue regeneration matrix that enhances cell-to-cell and cell-to-matrix interactions to improve wound healing outcomes. The company addresses the gap in regenerative medicine technology between cell therapy and traditional bandages, providing a platform for chronic wound care and potential organ manufacturing.

Cells for Cells develops advanced regenerative medicine therapies and implants for chronic diseases, utilizing tissue engineering, biomaterials, and cell/exosome therapies. They also create life science tools for research acceleration, with a strategy for out-licensing these technologies.

This company provides stem cell therapy and regenerative medicine services for orthopedic injuries, cancer, autoimmune issues, and neuro-degenerative disorders. Their treatments utilize stem cells to enhance healing and recovery processes for patients.

The startup specializes in gene editing techniques for pigs, specifically targeting modifications that facilitate xenotransplantation of organs, tissues, and cells. This approach aims to provide viable transplant options for patients suffering from organ failure, thereby improving their health outcomes and survival rates.

BlackGenn integrates synthetic biology, genomics, metagenomics, and metabolomics to expedite the development of new bioproducts. The startup addresses the slow and costly process of bioproduct generation by streamlining the research and development pipeline.

This startup produces fish feed using cellular aquaculture techniques, providing a sustainable alternative to traditional wild fishing methods. By enabling the cultivation of healthier and safer fish meat, the company addresses the environmental impact and food safety concerns associated with conventional seafood consumption.

Rede Nano Saúde is a nanotechnology network that accelerates the development of nano-products for tissue regeneration and medical treatments. It connects scientific research with the productive sector through specialized analysis, development, and consulting services, supporting entrepreneurship in nanomedicine.

The company develops a biotechnology platform utilizing recombinant viral vector technology to create autologous dendritic cell-based therapeutic vaccines for patients with chronic viral infections, such as HIV and hepatitis. This platform enables the rapid development of targeted therapies, addressing the need for effective treatments in chronic viral disease management.

The biotechnology company specializes in the development of biological therapies and vaccines tailored for the Latin American market, utilizing various technological platforms for biologic-based medicine. It provides essential services to innovators, enabling rapid responses to infectious diseases and enhancing biosecurity measures.

PrimeVax Immuno-Oncology, Inc. is developing a one-time, one-week cancer treatment using a live, attenuated strain of the dengue virus combined with autologous dendritic cells to elicit a robust immune response against late-stage cancers. This approach targets treatment-resistant tumors by leveraging the dengue virus's immuno-stimulatory properties to enhance systemic anti-tumor activity while maintaining a high safety profile.

ANCOR TECMIN enhances non-ferrous metal electrowinning and electrorefining operations with advanced electrolytic cell technology and custom composite capping boards. They also provide tankhouse rehabilitation services to optimize performance and product quality for mineral processing plants.

Nuwacell specializes in the research, development, and production of induced pluripotent stem cell (iPSC)-derived therapies for clinical applications. The company addresses the need for effective cell-based treatments in regenerative medicine by providing scalable and reliable cell therapy products.

Cell Farm is the first clean meat startup in LATAM, utilizing a standardized biotechnology process to cultivate meat from animal stem cells. This approach addresses the environmental and ethical concerns associated with traditional meat production by providing a sustainable alternative that reduces resource consumption and animal welfare issues.

The startup develops gene editing technology that directs cells to utilize error-free repair pathways, minimizing cellular toxicity while enabling large genomic edits. This approach aims to create genetic cures for liver and pancreatic diseases by addressing the challenges of precise DNA manipulation for therapeutic applications.

Isla Technologies develops a minimally invasive cell implant that regulates insulin production for individuals with poorly controlled type 1 diabetes. This technology aims to reduce the frequency of severe hypoglycemic episodes and improve overall glycemic control.

resistanceBio develops oncology drugs that focus on understanding and preventing drug resistance by mimicking the long-term evolution of cancer in a controlled environment. Their platform enables the identification of resistance pathways and the development of longer-lasting therapies, addressing the critical issue of treatment-resistant cancer that contributes to 90% of cancer mortality.

This company manufactures assay reagents using a unique amber glass technology that encapsulates pre-formulated biologic reagents. This technology automates and standardizes workflows for biopharmaceutical manufacturing and cell therapy, applicable to antibodies and enzymes.

Engage Bio has developed the Tethosome platform, a non-viral DNA delivery system that enhances therapeutic DNA expression by over 100-fold while remaining invisible to immune sensors. This technology addresses the challenges of potency and toxicity in genetic medicine, enabling safe, durable, and redosable treatments for cancer and other diseases.